Shares of Travere Therapeutics, Inc. (TVTX) soared 5.23% on Wednesday, November 1st, 2024, driven primarily by analyst optimism surrounding the biopharmaceutical company despite its recent mixed earnings report.
On the same day, Barclays analyst Carter Gould maintained a Buy rating on TVTX stock, with a price target that suggests further upside potential. This positive analyst sentiment likely fueled bullish momentum in the stock, as multiple other analysts also weighed in with insights on the healthcare sector.
Meanwhile, TVTX reported its third-quarter earnings results for the period ended September 30th. While the company missed revenue expectations, posting a 94.9% year-over-year decline to $1.9 million, it beat on earnings per share (EPS), reporting an adjusted loss of $0.70 per share compared to analysts' expectations of a $0.68 loss. This mixed performance may have contributed to some volatility in the stock's trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。